SCHEMBL13612814

SCHEMBL13612814

CN1C(=O)[C@H](C2CCCCC2)NCCOc2ccccc2CCCNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]1C(C)(C)O

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 20/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13612779 0.97 GHSR (0.79) GHSR
SCHEMBL13612810 0.95 GHSR (0.67) GHSR
SCHEMBL13626801 0.95 GHSR (0.75) GHSR
SCHEMBL13612803 0.94 GHSR (0.76) GHSR
SCHEMBL13612807 0.94 GHSR (0.76) GHSR
SCHEMBL13612761 0.92 GHSR (0.71) GHSR
SCHEMBL13612759 0.91 GHSR (0.80) GHSR
SCHEMBL13612765 0.91 GHSR (0.80) GHSR
SCHEMBL13612788 0.88 GHSR (0.76) GHSR
SCHEMBL13612798 0.87 GHSR (0.74) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275648-A1 MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME OCERA THERAPEUTICS, INC. 2009-11-05 US disclosed
US-20090275648-A1 MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME OCERA THERAPEUTICS, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275648-A1 MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME GHSR, GIPR, GHRHR GHSR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.